Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of carfilzomib weekly 20/56mg/m² plus lenalidomide and dexamethasone regimen in patients with early relapsed refractory multiple myeloma (RRMM)

Trial Profile

Efficacy and safety of carfilzomib weekly 20/56mg/m² plus lenalidomide and dexamethasone regimen in patients with early relapsed refractory multiple myeloma (RRMM)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 29 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top